CPC A61K 38/4886 (2013.01) [A61K 9/0073 (2013.01); A61K 9/16 (2013.01); A61K 9/50 (2013.01); A61K 45/06 (2013.01); A61L 29/16 (2013.01); A61L 31/16 (2013.01); A61P 31/00 (2018.01); A61P 31/06 (2018.01); C12N 9/6489 (2013.01); A61L 2300/254 (2013.01); A61L 2300/404 (2013.01); A61L 2300/45 (2013.01); C12Y 304/24075 (2013.01); Y02A 50/30 (2018.01)] | 13 Claims |
1. A pharmaceutical composition comprising:
a recombinantly engineered enzyme that is a glycyl-glycine endopeptidase;
an anti-Mycobacterial compound that is effective against a Mycobacteria which acts synergistically with the glycyl-glycine endopeptidase, wherein the anti-Mycobacterial compound is selected from the group consisting of cycloserine, isoniazid, and ethambutol; and
antibodies against Mycobacteria; and
wherein the composition is encapsulated and the encapsulated composition is biodegradable and provides a slow-release or a timed-release of enzyme when administered to a patient.
|